Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors.
It is being tested as a possible treatment for cancer.
In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.
[1] Two early stage clinical trials have reported encouraging results.
This pharmacology-related article is a stub.